{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:12:22Z","timestamp":1790115142213,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00120-026-02811-w","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:25:58Z","timestamp":1774963558000},"page":"470-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fr\u00fcherkennung des Prostatakarzinoms\u00a0\u2013 Empfehlungen der aktualisierten S3-Leitlinie 2025","Early detection of prostate cancer\u2014recommendations of the updated S3\u00a0guideline 2025"],"prefix":"10.1007","volume":"65","author":[{"given":"Rouvier","family":"Al-Monajjed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Franiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2811_CR1","unstructured":"RKIKrebsregisterdaten Zf (ed) (2022) Krebs in Deutschland. Robert Koch Institut"},{"key":"2811_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00120-024-02275-w","volume":"63","author":"TS Worst","year":"2024","unstructured":"Worst\u00a0TS, Surovtsova\u00a0I, Vogel\u00a0T et\u00a0al (2024) Incidence, therapy, and prognosis of prostate cancer in Baden-W\u00fcrttemberg: analysis based on cancer registry data. Urologie 63:681\u2013692","journal-title":"Urologie"},{"key":"2811_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James\u00a0ND, Tannock\u00a0I, N\u2019Dow\u00a0J et\u00a0al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403:1683\u20131722","journal-title":"Lancet"},{"key":"2811_CR4","doi-asserted-by":"crossref","unstructured":"de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group. A\u00a0Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol. 2023;85(4):426\u2013434","DOI":"10.1016\/j.eururo.2023.03.016"},{"key":"2811_CR5","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C, Albers\u00a0P, Herkommer\u00a0K et\u00a0al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer 150:1861\u20131869","journal-title":"Int J Cancer"},{"key":"2811_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt\u00a0O, Godtman\u00a0RA, Jiborn\u00a0T et\u00a0al (2024) Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol 85:207\u2013214","journal-title":"Eur Urol"},{"key":"2811_CR7","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson\u00a0J, M\u00e5nsson\u00a0M, Wallstr\u00f6m\u00a0J et\u00a0al (2022) Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N\u00a0Engl J Med 387:2126\u20132137","journal-title":"N Engl J Med"},{"key":"2811_CR8","doi-asserted-by":"crossref","unstructured":"Fazekas T, Shim SR, Basile G, et\u00a0al.: Magnetic Resonance Imaging in Prostate Cancer Screening: A\u00a0Systematic Review and Meta-Analysis. JAMA Oncol 2024.","DOI":"10.1001\/jamaoncol.2024.0734"},{"key":"2811_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2023","volume":"346","author":"AJ Vickers","year":"2013","unstructured":"Vickers\u00a0AJ, Ulmert\u00a0D, Sjoberg\u00a0DD et\u00a0al (2013) Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 346:f2023","journal-title":"BMJ"},{"key":"2811_CR10","unstructured":"Tillmanns H:\u00a0Fr\u00fcherkennung: Die Teilnahmeraten sind oft noch zu niedrig. WIDO - Wissenschaftliches Institut der AOK2020."},{"issue":"6","key":"2811_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute\u00a0A, Becker\u00a0N, Lakes\u00a0J et\u00a0al (2023) Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol 6(6):566\u2013573. https:\/\/doi.org\/10.1016\/j.euo.2023.09.008","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2811_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","volume":"86","author":"A Krilaviciute","year":"2024","unstructured":"Krilaviciute\u00a0A, Kaaks\u00a0R, Seibold\u00a0P et\u00a0al (2024) Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Eur Urol 86(6):493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.030","journal-title":"Eur Urol"},{"issue":"1","key":"2811_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2010.1923","volume":"305","author":"S Studenski","year":"2011","unstructured":"Studenski\u00a0S, Perera\u00a0S, Patel\u00a0K et\u00a0al (2011) Gait speed and survival in older adults. JAMA 305(1):50\u201358. https:\/\/doi.org\/10.1001\/jama.2010.1923","journal-title":"JAMA"},{"key":"2811_CR14","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost\u00a0FH, Osses\u00a0DF, Nieboer\u00a0D et\u00a0al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:Cd012663","journal-title":"Cochrane Database Syst Rev"},{"key":"2811_CR15","first-page":"763","volume":"193","author":"T Franiel","year":"2021","unstructured":"Franiel\u00a0T, Asbach\u00a0P, Beyersdorff\u00a0D et\u00a0al (2021) mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning Protocol. RoFo 193:763\u2013777","journal-title":"RoFo"},{"key":"2811_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots\u00a0IG, Padhani\u00a0AR (2021) Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int 127:175\u2013178","journal-title":"BJU Int"},{"key":"2811_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111436","volume":"175","author":"M Quentin","year":"2024","unstructured":"Quentin\u00a0M, Boschheidgen\u00a0M, Radtke\u00a0JP et\u00a0al (2024) MRI in-bore biopsy following MRI\/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer. Eur J Radiol 175:111436","journal-title":"Eur J Radiol"},{"key":"2811_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/JU.0000000000000757","volume":"204","author":"MA Pagniez","year":"2020","unstructured":"Pagniez\u00a0MA, Kasivisvanathan\u00a0V, Puech\u00a0P, Drumez\u00a0E, Villers\u00a0A, Olivier\u00a0J (2020) Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. J\u00a0Urol 204:24\u201332","journal-title":"J Urol"},{"key":"2811_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","volume":"75","author":"AR Alberts","year":"2019","unstructured":"Alberts\u00a0AR, Roobol\u00a0MJ, Verbeek\u00a0JFM et\u00a0al (2019) Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol 75:310\u2013318","journal-title":"Eur Urol"},{"key":"2811_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","volume":"86","author":"JC Hu","year":"2024","unstructured":"Hu\u00a0JC, Assel\u00a0M, Allaf\u00a0ME et\u00a0al (2024) Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol 86:61\u201368","journal-title":"Eur Urol"},{"key":"2811_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000003788","volume":"211","author":"BM Mian","year":"2024","unstructured":"Mian\u00a0BM, Feustel\u00a0PJ, Aziz\u00a0A et\u00a0al (2024) Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial. J\u00a0Urol 211:205\u2013213","journal-title":"J Urol"},{"key":"2811_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","volume":"7","author":"G Ploussard","year":"2024","unstructured":"Ploussard\u00a0G, Barret\u00a0E, Fiard\u00a0G et\u00a0al (2024) Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol 7:1080\u20131087","journal-title":"Eur Urol Oncol"},{"key":"2811_CR23","doi-asserted-by":"crossref","unstructured":"Heetman JG, Lavalaye J, Polm PD, et\u00a0al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT). Eur Urol Oncol. 2024;7(2):204\u2013210. https:\/\/doi.org\/10.1016\/j.euo.2023.05.004","DOI":"10.1016\/j.euo.2023.05.004"},{"key":"2811_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS, Lawrentschuk\u00a0N, Francis\u00a0RJ et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"2811_CR25","doi-asserted-by":"crossref","unstructured":"Pritchard CC, Mateo J, Walsh MF, et\u00a0al.: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 2016; 375: 443\u201353.","DOI":"10.1056\/NEJMc1611137"},{"key":"2811_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA et\u00a0al (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N\u00a0Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"2811_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","volume":"69","author":"G Sauter","year":"2016","unstructured":"Sauter\u00a0G, Steurer\u00a0S, Clauditz\u00a0TS et\u00a0al (2016) Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. Eur Urol 69:592\u2013598","journal-title":"Eur Urol"},{"key":"2811_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bju.16727","volume":"136","author":"II de Vos","year":"2025","unstructured":"de Vos\u00a0II, Marenghi\u00a0C, Badenchini\u00a0F, PRIAS consortium et\u00a0al (2025) Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int 136:245\u2013253","journal-title":"BJU Int"},{"key":"2811_CR29","unstructured":"Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2025) S3-Leitlinie Prostatakarzinom. Version 8.0. AWMF-Registernummer 043-022OL."},{"key":"2811_CR30","first-page":"1320","volume":"370","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der\u00a0FH et\u00a0al (2014) Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 370:1320\u20131328","journal-title":"New Engl J Med"},{"issue":"4","key":"2811_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","volume":"85","author":"A de Vos II","year":"2023","unstructured":"de Vos\u00a0A II, Meertens\u00a0A, Hogenhout\u00a0R et\u00a0al (2023) A detailed evaluation of the effect of PSA-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the ERSPC. Eur Urol 85(4):426\u2013434","journal-title":"Eur Urol"},{"key":"2811_CR32","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C, Albers\u00a0P, Herkommer\u00a0K et\u00a0al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial. Int J Cancer 150:1861\u20131869","journal-title":"Int J Cancer"},{"key":"2811_CR33","unstructured":"Krilaviciute A, Kaaks R, Seibold P et\u00a0al. Risk-adapted screening for prostate cancer\u2014redefining the low-risk group by data from the PROBASE trial. Eur Urol 2024 (in press)."},{"key":"2811_CR34","volume":"368","author":"N Pashayan","year":"2020","unstructured":"Pashayan\u00a0N et\u00a0al (2020) Benefits and harms of prostate cancer screening: an analysis of randomised trials. BMJ 368:m478","journal-title":"BMJ"},{"key":"2811_CR35","doi-asserted-by":"crossref","unstructured":"Fazekas T, Shim SR, Basile G et\u00a0al. Magnetic resonance imaging in prostate cancer screening: a\u00a0systematic review and meta-analysis. JAMA Oncol 2024.","DOI":"10.1001\/jamaoncol.2024.0734"},{"key":"2811_CR36","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost\u00a0FH, Osses\u00a0DF, Nieboer\u00a0D et\u00a0al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:CD012663","journal-title":"Cochrane Database Syst Rev"},{"key":"2811_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2023","volume":"346","author":"AJ Vickers","year":"2013","unstructured":"Vickers\u00a0AJ, Ulmert\u00a0D, Sj\u00f6berg\u00a0DD et\u00a0al (2013) Strategy for detection of prostate cancer based on relation between PSA at age 40\u201355 and long-term risk of metastasis. BMJ 346:f2023","journal-title":"BMJ"},{"key":"2811_CR38","unstructured":"Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2025) S3-Leitlinie Prostatakarzinom. Version 8.0. AWMF-Registernummer 043-022OL."}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02811-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:57:40Z","timestamp":1777460260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02811-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2811"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02811-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Al-Monajjed, P.\u00a0Albers, T.\u00a0Franiel, T.\u00a0K\u00f6tter, G.\u00a0Kristiansen, K.\u00a0Herrmann und T.\u00a0Wiegel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}